4.3 Review

A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation

Journal

CLINICAL THERAPEUTICS
Volume 23, Issue 10, Pages 1628-1636

Publisher

EXCERPTA MEDICA INC
DOI: 10.1016/S0149-2918(01)80134-X

Keywords

atrial fibrillation; anticoagulation; clinical practice; efficacy; safety

Ask authors/readers for more resources

Background. Warfarin therapy has proved safe and effective in a number of randomized controlled trials of stroke prophylaxis in patients with nonvalvular atrial fibrillation (NVAF), reducing the risk of stroke in these patients by two thirds. However, participants in the clinical trials were carefully selected and younger than patients in actual clinical practice. Objective: This analysis sought to determine whether the results of clinical trials in patients with NVAF can be extrapolated to the general population seen in clinical practice. Methods: A MEDLINE search from 1966 to the present was used to identify observational trials of anticoagulation in patients with NVAF that addressed warfarin use, anti-coagulation control, efficacy, and complications. The search terms used were atrial fibrillation and anticoagulation. Results: Although warfarin prophylaxis against stroke in patients with NVAF appeared to be as well tolerated and effective in clinical practice as in clinical trials, it was generally underused, particularly in the elderly. Anticoagulation control was not as good in clinical practice as in clinical trials, although the rates of stroke and major bleeding were comparable. Conclusions: Judicious use of warfarin, tailored to individual stroke risk, seems to be a reasonable policy. Warfarin therapy increases quality-adjusted survival in patients at high risk for stroke, and it is recommended for medium-risk patients unless their risk of bleeding is high or their quality of life while taking warfarin would be poor. Patients at a low risk for stroke will have equivalent health outcomes and incur lower costs if treated with aspirin. Despite the increased risk of hemorrhage in elderly patients, the net benefit of warfarin therapy is greater in this age group because of the higher risk of stroke. Active involvement of patients and their caregivers in an anticoagulation service setting may improve outcomes of anticoagulation therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available